There is no difference in efficacy between six and eight cycles of R-CHOP-21 to treat diffuse large B-cell lymphoma (DLBCL), according to a study published in ESMO Open.
“R-CHOP-21 has been the standard treatment for DLBCL, but there is a paucity of evidence focusing on the number of cycles of regimens,” the researchers wrote. They conducted a retrospective study comprised of 685 patients with newly diagnosed DLBCL who were identified in three institutions from 2007 to 2017. Patients treated with six cycles were matched by propensity score with those treated with eight. Overall, this method yielded 138 patient pairs.
According to the results, eight cycles of R-CHOP did not significantly improve overall survival (OS) by measure of Cox proportional hazards modeling (HR=0.849, 95% CI, 0.453-1.588, P=0.608). The researchers noted that the occurrence of adverse events did not differ between six and eight cycles.
“Even considering the impact of RDI, six cycles of the initial standard regimen for DLBCL is not inferior to eight cycles,” the researchers wrote.